Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Zou, Qiong ^a,b   Xiong, Li ^b   Yang, Zhulin ^b   Lv, Fang ^b   Yang, Leping ^b   Miao, Xiongying ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chronic cholecystitis; Gallbladder neoplasms; Gallbladder polyp; High mobility group A2; Immunohistochemsitry; Mobility related protein 1 CD9

Indexed keywords

CD9 ANTIGEN; HIGH MOBILITY GROUP A2 PROTEIN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHRONIC CHOLECYSTITIS; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; GALLBLADDER EPITHELIUM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYP; POSTOPERATIVE PERIOD; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOMATOUS POLYPS; ADULT; AGED; ANTIGENS, CD9; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CHOLECYSTITIS; FEMALE; GALLBLADDER; GALLBLADDER NEOPLASMS; HMGA2 PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84861215687     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-92     Document Type: Article

References (19)

1. Jones RS. Carcinoma of the gallbladder. Surg Clin North Am 1990, 70:1419-1428.
2. Carriaga MT, Henson DE. Liver, gallbladder, extraHepatic bile ducts, and pancreas. Cancer 1995, 75:171-190. 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2, 8000995.
3. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 2008, 14:2334-2340. 10.1158/1078-0432.CCR-07-4667, 18413822.
4. Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, Resar LM. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 2009, 22:43-49. 10.1038/modpathol.2008.140, 2769577, 18843278.
5. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 2007, 46:503-511. 10.1002/mc.20235, 17477356.
6. Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, Pierantoni GM, Santoro M, Fusco A. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 2008, 44:1015-1021. 10.1016/j.ejca.2008.02.039, 18375116.
7. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specific gene HMGA2 in squcell carcinomas of the oral cavity. Cancer Res 2004, 64:2024-2029. 10.1158/0008-5472.CAN-03-1855, 15026339.
8. Malek A, Bakhidze E, Noske A. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008, 123:348-356. 10.1002/ijc.23491, 18452175.
9. Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, Nishida M, Katsube F, Watabe K, Kiso S, Tsutsui S, Tamura S, Shinomura Y, Hayashi N. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol 2009, 44:889-896. 10.1007/s00535-009-0081-3, 19468669.
10. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009, 9:40-55. 10.1038/nrc2543, 19078974.
11. Bari R, Zhang YH, Zhang F, Wang NX, Stipp CS, Zheng JJ, Zhang XA. Transmembrane interactions are needed for KALL/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol 2009, 174:647-660. 10.2353/ajpath.2009.080685, 2630572, 19116362.
12. Gesierich S, Paret C, Hidebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zöller M. Colocalization of the tetraspanins, Co-029 and CD151, with integrins in human pancreatic adenocarcinoma: Impact on cell motility. Clin Cancer Res 2005, 11:2840-2852. 10.1158/1078-0432.CCR-04-1935, 15837731.
13. Kanetaka K, Sakamoto M, Yamamoto Y, Yamasaki S, Lanza F, Kanematsu T, Hirohashi S. Overexpression of tetraspanin Co-029 in hepatocellular carcinoma. J Hepatol 2001, 35:637-642. 10.1016/S0168-8278(01)00183-0, 11690710.
14. Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 1998, 4:1507-1510.
15. Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC, Davis BJ. Loss of expression and altered localization of KAL1 and cd9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol 2002, 86:69-78. 10.1006/gyno.2002.6729, 12079303.
16. Dalie M, Chenguan B. Observe and judge the results with immunohistochemical positive marks. J Clin Exp Pathol 2003, 19:557-559.
17. Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol 2007, 17:72-79. 10.1016/j.tcb.2006.12.001, 2442274, 17169561.
18. Wunderlich V, Bottger M. High-mobility-group proteins and cancer: an emerging link. J Cancer Res Clin Oncol 1997, 123:133-140.
19. Arihiro K, Kaneko M, Fujii S, Inai K. Loss of CD9 with expression of CD31 and VEGF in breast carcinoma, as predictive factors of lymph node metastasis. Breast Cancer 1998, 5:131-138. 10.1007/BF02966685, 11091638.